A critical analysis about the supposed role of azithromycin in the treatment of covid-19
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Revista Ciências em Saúde |
| Texto Completo: | https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1184 |
Resumo: | After over one year, the coronavirus disease 2019 (covid-19) has still affected millions of people. For this reason, global efforts to promote better treatment of covid-19 have been undertaken focused on the repurposing of existing medications.In Brazil, azithromycin, a broad-spectrum antibiotic, has been used in association with other drugs as an immunomodulatory, anti-inflammatory, and anti-viral agent, regardless of bacterial co-infection. Indeed, data from experimental studies have demonstrated the capacity of this drug in reducing the production of infection-induced pro-inflammatory cytokines, such as IL-8, IL-6, and TNF-alpha. However, observational studies revealed conflicting results regarding its effect, whereas well-conducted clinical trials have not shown a considerable effect of this agent on the improvement of clinical outcomes. This narrative review addressed the possible role of this antibiotic in the management of covid-19, based on data from clinical and preclinical studies. |
| id |
RCS_e8857bee4f981ec1fe91d71ddc87f431 |
|---|---|
| oai_identifier_str |
oai:ojs.portalrcs.hcitajuba.org.br:article/1184 |
| network_acronym_str |
RCS |
| network_name_str |
Revista Ciências em Saúde |
| repository_id_str |
|
| spelling |
A critical analysis about the supposed role of azithromycin in the treatment of covid-19Uma análise crítica sobre o suposto papel da azitromicina no tratamento da covid-19anti-infective agentsazithromycincovid-19SARS-CoV-2anti-infecciososazitromicinacovid-19SARS-CoV-2After over one year, the coronavirus disease 2019 (covid-19) has still affected millions of people. For this reason, global efforts to promote better treatment of covid-19 have been undertaken focused on the repurposing of existing medications.In Brazil, azithromycin, a broad-spectrum antibiotic, has been used in association with other drugs as an immunomodulatory, anti-inflammatory, and anti-viral agent, regardless of bacterial co-infection. Indeed, data from experimental studies have demonstrated the capacity of this drug in reducing the production of infection-induced pro-inflammatory cytokines, such as IL-8, IL-6, and TNF-alpha. However, observational studies revealed conflicting results regarding its effect, whereas well-conducted clinical trials have not shown a considerable effect of this agent on the improvement of clinical outcomes. This narrative review addressed the possible role of this antibiotic in the management of covid-19, based on data from clinical and preclinical studies.Após mais de um ano, a doença coronavírus 2019 (covid-19) ainda afeta milhões de pessoas. Por esta razão, os esforços globais para promover um melhor tratamento para covid-19 têm sido realizados com foco no reaproveitamento de medicamentos existentes. No Brasil, a azitromicina, um antibiótico de amplo espectro, tem sido utilizada em associação com outras drogas como agente imunomodulador, antiinflamatório e antiviral, independentemente da coinfecção bacteriana. De fato, dados de estudos experimentais demonstraram a capacidade dessa droga em reduzir a produção de citocinas pró-inflamatórias induzidas por infecção, como IL-8, IL-6 e TNF-alfa. No entanto, estudos observacionais revelaram resultados conflitantes quanto ao seu efeito, ao passo que ensaios clínicos bem conduzidos não demonstraram um efeito considerável desse agente na melhora dos desfechos clínicos. Esta revisão narrativa teve como objetivo abordar o possível papel desse antibiótico no tratamento de covid-19, com base em dados de estudos clínicos e pré-clínicos.AISI/HCI2021-12-22info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer reviewedAvaliado pelos parestextoinfo:eu-repo/semantics/otherapplication/pdfhttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/118410.21876/rcshci.v11i4.1184Revista Ciências em Saúde; v. 11 n. 4 (2021): Outubro a Dezembro de 2021; 11-21Health Sciences Journal; Vol 11 No 4 (2021): October to December 2021; 11-212236-378510.21876/rcshci.v11i4reponame:Revista Ciências em Saúdeinstname:Hospital de Clínicas de Itajubáinstacron:HCIenghttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1184/751Copyright (c) 2021 Revista Ciências em Saúdehttps://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessSantana, Ricardo Ruan Barbosa, Bárbara Oliva Soares, José Rivaldo de OliveiraColombo, Rayssa MieloSantos, Victória Rafaela Amaral, Ricardo GuimarãesAndrade, Luciana Nalone2021-12-29T22:19:11Zoai:ojs.portalrcs.hcitajuba.org.br:article/1184Revistahttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zeroPUBhttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/oaircs@hcitajuba.org.br||rcsfmit@medicinaitajuba.com.br2236-37852236-3785opendoar:2021-12-29T22:19:11Revista Ciências em Saúde - Hospital de Clínicas de Itajubáfalse |
| dc.title.none.fl_str_mv |
A critical analysis about the supposed role of azithromycin in the treatment of covid-19 Uma análise crítica sobre o suposto papel da azitromicina no tratamento da covid-19 |
| title |
A critical analysis about the supposed role of azithromycin in the treatment of covid-19 |
| spellingShingle |
A critical analysis about the supposed role of azithromycin in the treatment of covid-19 Santana, Ricardo Ruan anti-infective agents azithromycin covid-19 SARS-CoV-2 anti-infecciosos azitromicina covid-19 SARS-CoV-2 |
| title_short |
A critical analysis about the supposed role of azithromycin in the treatment of covid-19 |
| title_full |
A critical analysis about the supposed role of azithromycin in the treatment of covid-19 |
| title_fullStr |
A critical analysis about the supposed role of azithromycin in the treatment of covid-19 |
| title_full_unstemmed |
A critical analysis about the supposed role of azithromycin in the treatment of covid-19 |
| title_sort |
A critical analysis about the supposed role of azithromycin in the treatment of covid-19 |
| author |
Santana, Ricardo Ruan |
| author_facet |
Santana, Ricardo Ruan Barbosa, Bárbara Oliva Soares, José Rivaldo de Oliveira Colombo, Rayssa Mielo Santos, Victória Rafaela Amaral, Ricardo Guimarães Andrade, Luciana Nalone |
| author_role |
author |
| author2 |
Barbosa, Bárbara Oliva Soares, José Rivaldo de Oliveira Colombo, Rayssa Mielo Santos, Victória Rafaela Amaral, Ricardo Guimarães Andrade, Luciana Nalone |
| author2_role |
author author author author author author |
| dc.contributor.author.fl_str_mv |
Santana, Ricardo Ruan Barbosa, Bárbara Oliva Soares, José Rivaldo de Oliveira Colombo, Rayssa Mielo Santos, Victória Rafaela Amaral, Ricardo Guimarães Andrade, Luciana Nalone |
| dc.subject.por.fl_str_mv |
anti-infective agents azithromycin covid-19 SARS-CoV-2 anti-infecciosos azitromicina covid-19 SARS-CoV-2 |
| topic |
anti-infective agents azithromycin covid-19 SARS-CoV-2 anti-infecciosos azitromicina covid-19 SARS-CoV-2 |
| description |
After over one year, the coronavirus disease 2019 (covid-19) has still affected millions of people. For this reason, global efforts to promote better treatment of covid-19 have been undertaken focused on the repurposing of existing medications.In Brazil, azithromycin, a broad-spectrum antibiotic, has been used in association with other drugs as an immunomodulatory, anti-inflammatory, and anti-viral agent, regardless of bacterial co-infection. Indeed, data from experimental studies have demonstrated the capacity of this drug in reducing the production of infection-induced pro-inflammatory cytokines, such as IL-8, IL-6, and TNF-alpha. However, observational studies revealed conflicting results regarding its effect, whereas well-conducted clinical trials have not shown a considerable effect of this agent on the improvement of clinical outcomes. This narrative review addressed the possible role of this antibiotic in the management of covid-19, based on data from clinical and preclinical studies. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-12-22 |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer reviewed Avaliado pelos pares texto info:eu-repo/semantics/other |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1184 10.21876/rcshci.v11i4.1184 |
| url |
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1184 |
| identifier_str_mv |
10.21876/rcshci.v11i4.1184 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1184/751 |
| dc.rights.driver.fl_str_mv |
Copyright (c) 2021 Revista Ciências em Saúde https://creativecommons.org/licenses/by-nc-sa/4.0 info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Copyright (c) 2021 Revista Ciências em Saúde https://creativecommons.org/licenses/by-nc-sa/4.0 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
AISI/HCI |
| publisher.none.fl_str_mv |
AISI/HCI |
| dc.source.none.fl_str_mv |
Revista Ciências em Saúde; v. 11 n. 4 (2021): Outubro a Dezembro de 2021; 11-21 Health Sciences Journal; Vol 11 No 4 (2021): October to December 2021; 11-21 2236-3785 10.21876/rcshci.v11i4 reponame:Revista Ciências em Saúde instname:Hospital de Clínicas de Itajubá instacron:HCI |
| instname_str |
Hospital de Clínicas de Itajubá |
| instacron_str |
HCI |
| institution |
HCI |
| reponame_str |
Revista Ciências em Saúde |
| collection |
Revista Ciências em Saúde |
| repository.name.fl_str_mv |
Revista Ciências em Saúde - Hospital de Clínicas de Itajubá |
| repository.mail.fl_str_mv |
rcs@hcitajuba.org.br||rcsfmit@medicinaitajuba.com.br |
| _version_ |
1797068963268526080 |